Autologous tumor-associated antigen-Major Histocompatibility Complex (TAA-MHC) (TAA-MHC)

Autologous tumor-associated antigens (TAAs) presented on the Major Histocompatibility Complex (MHC) are a critical class of personalized therapeutic targets in oncology. These targets consist of short peptide fragments—derived from either mutated proteins (neoantigens) or overexpressed self-proteins—that are displayed on the surface of cancer cells by MHC molecules for recognition by T-cell receptors (TCRs). In a healthy physiological state, the immune system utilizes these complexes to identify and eliminate aberrant cells; however, tumors often develop mechanisms to evade this detection, such as downregulating MHC expression or exploiting immune checkpoints (PubMed, 2022). Modern immunotherapies, including personalized mRNA vaccines like mRNA-4157 and adoptive cell therapies like TILs, are designed to specifically target these patient-unique pMHC signatures to induce a robust and specific anti-tumor response (Moderna, 2024; BioNTech, 2023). Because these antigens are often highly specific to the individual's tumor, they offer the potential for high precision with minimal damage to healthy tissues compared to conventional therapies. However, the effectiveness of targeting these complexes is contingent upon the accurate identification of immunogenic peptides and the maintenance of MHC presentation by the tumor cells.

Other names

Patient-specific tumor antigensNeoantigen-MHC complexesTumor-specific antigen (TSA) presented on HLAPeptide-MHC (pMHC) complexAutologous neoepitopes

Therapeutic agents targeting these complexes function by either stimulating the patient's endogenous immune system to recognize specific pMHC targets (active immunotherapy via vaccines) or by providing ex vivo expanded or engineered T-cells (passive immunotherapy via TIL or TCR-T) that bind the TAA-MHC complex with high affinity, triggering the release of cytotoxic granules and tumor cell apoptosis (Nature Reviews Cancer, 2021; NCI, 2023).